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Pentoxifylline (PTX) is one of several
methylxanthine compounds used as a hemorheolog-
ic agent for the treatment of peripheral vascular dis-
ease and intermittent claudication. In addition to its
ability to improve microcirculation, PTX also
proves an anti-tumor necrosis factor-alpha (TNFα)
action and immunomodulatory properties (1). In
vivo, PTX is reduced by carbonyl reductase to a
pharmacologically active stereoisomeric hydroxyl
metabolite M1 (Figure 1). This biotransformation
process is rapidly reversible and takes place both in
erythrocytes (2) and liver microsomes and cytosol
(3) and probably also in some other tissues, such as
lung and kidney. 
The biotransformation of PTX to M1 is highly
stereoselective in favor of the (+)-(S)-M1 enan-
tiomer formation, in both the in vitro and in vivo
study (4). The less favored and biologically active 
(-)-(R)-M1 enantiomer (lisofylline) accounts only
for 5-10% of the total metabolite M1 in blood (3).
Previously published analytical data indicate an
increase of the formation of (-)-(R)-M1 from PTX
in, for example, the presence of ciprofloxacin (5).
In human liver microsomes, enantiomer (+)-(S)-M1
is exclusively converted to PTX, whereas approxi-
mately 45% of (-)-(R)-M1 oxidation is accounted
for by the formation of PTX and the balance of
aliphatic diols (6). CYP1A2 is the highest affinity
enzyme catalyzing the biotransformation of (-)-(R)-
M1 to PTX (7), whereas CYP3A4 and CYP2A6
isozymes catalyze the metabolism of (-)-(R)-M1 to a
diol (6).
Lisofylline, originally developed as a novel
anti-inflammatory compound which reduces inflam-
matory cytokine production and its activity,
improves beta-cell mitochondrial metabolism, regu-
lates immune activities and reduces cellular damage
due to ischemic reperfusion, hypoxia or autoim-
mune disease (8). It has been proven that the (-)-(R)-
M1 enantiomer is several hundred times more effec-
tive than its parent compound, PTX, at inhibiting the
activity of inflammatory cytokines (9). Lisofylline
modulates stress associated changes in lipid metab-
olism and has been tested to modify the toxicity for
patients undergoing intensive dose cytotoxic thera-
py and to prevent multiorgan failure in acute respi-
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ratory distress syndrome (10). It has been reported
that (-)-(R)-M1 can decrease the dysfunction of rat
pancreatic islets caused by interleukin-1 beta (IL-
1β) (11). 
Several analytical methods using gas chro-
matography (12, 13) and reversed-phase HPLC with
ultra-violet detection (14, 15) have been developed
for the determination of PTX and its major metabo-
lites in plasma and also for the separation of the M1
enantiomers after chiral derivatization (4). Recently,
a liquid chromatography-tandem mass spectrometry
method has been described to determine PTX and 
(-)-(R)-M1 in human and rabbit plasma (16). The
latter method has provided good results, but it was
achiral and involved expensive equipment not easi-
ly available.
The purpose of this study was to develop and
validate according to validation procedure parame-
ters and acceptance criteria based on USP XXIII
guidelines and FDA guidance (17), a direct, enan-
tioselective high-performance liquid chromatogra-
phy method with ultra-violet detection for the simul-
taneous quantification of PTX and (-)-(R)-M1 enan-




3,7-dihydropurine-2,6-dione, was obtained from




and the internal standard, 3,7-dihydro-1,3-dimethyl-
7-(2-chloroethyl)-xanthine, were supplied by the
Department of Chemical Technology and
Biotechnology of Drugs (Faculty of Pharmacy,
Jagiellonian University, Medical College, KrakÛw). 
HPLC grade hexane, 2-propanol, diethyl-
amine, methanol, acetonitrile, hydrochloric acid,
dichloromethane, chloroform, dihydropotassium
phosphate, orthophosphoric acid and natrium chlo-
ride were purchased from Merck (Darmstadt,
Germany). 
Pooled control serum and tissue samples were
obtained from adult male Wistar rats Krf:(WI)WV
(Charles River Laboratory, Germany), weighing
200 to 220 g. The study was approved by the
Institutional Animal Care and Ethics Committee.
Rats were injected intraperitoneally with thiopental
(60 mg ◊ kg
-1
), and blood samples were collected
from the left jugular vein. The serum was separated
by centrifugation (1500 g, 10 min) and stored at 
ñ 30OC until used. The tissue samples (liver, kidney,
lung, heart and spleen) were stored at ñ 80∞C until
assayed. 
Instrumentation and chromatographic conditions
The method validation was performed on a
ThermoSeparation Products HPLC system (San
Jose, CA, USA) with a variable wavelength UV-vis-
ible spectrophotometric detector (Spectra 100). The
elution profiles in the HPLC separations were mon-
itored by absorbance set at 275 nm at 0.02 AUFS.
Injections were done using a Rheodyne 7125 manu-
al injector (Alltech Associates, Deerfield, IL, USA)
fitted with a 50 mL sample loop (Supelpro, Supelco,
Germany). Chromatograms were recorded and inte-
grated with a model SP 4400 ChromJet integrator
(San Jose, CA, USA).
Analyses were performed on an amylose
ChiralPak AD (250 mm ◊ 4.6 mm i.d., 5 mm) ana-
lytical column (Daicel Chemical Industry, Tokyo,
Japan) protected by a Supelcosil LC-Si guard col-
umn (Supelco, Germany) and operated at room tem-
perature. Optimal separation of the compounds was
achieved using a normal mobile phase containing 
n-hexane and 2-propanol (84:16, v/v) with 0.01%
diethylamine and pumped through the system at a
flow rate of 1.5 mL ◊ min
-1
. 
Figure 1. Structures of pentoxifylline, lisofylline and internal stan-
dard.
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Preparation of standard solutions, calibration
curves and quality control samples
Stock solutions of PTX and (-)-(R)-M1 at a
concentration of 1000 mg ◊ mL
-1
and its working
solutions at concentrations of 0.1, 1, 2.5, 10, 25, 50,
500 and 1000 µg ◊ mL
-1
were prepared in methanol.
Similarly, a stock solution (1000 mg ◊ mL
-1
) and a
working solution (50 mg ◊ mL
-1
) of internal standard
was also prepared in methanol. Stock solutions and
all working standards were stored at 4OC.
Calibration curves were constructed by supple-
menting 50 mL of the appropriate working solution
to 0.45 mL of drug-free serum samples or to 0.45
mL of drug-free homogenate tissue samples.
Concentrations of the analytes were 0.01, 0.1, 0.25,
1, 2.5, 5, 50 and 100 mg ◊ mL
-1
. To all samples 50
mL of the internal standard working solution was
added. For serum and tissue samples, before sample
pretreatment, the mixture was vortexed briefly and
then incubated at 4OC for 15 min.
Quality control (QC) samples containing the
analytes were prepared at four different concentra-
tions along the calibration range (low at 0.015 mg ◊
mL
-1
, medium at 0.5 mg ◊ mL
-1
and 4 mg ◊ mL
-1
and
high at 80 mg ◊ mL
-1
) by spiking drug-free serum
and tissue samples with the analytes, as described
above, and kept frozen at ñ 30 and ñ 80OC, respec-
tively.
Sample preparation procedure in the animalís
treatment group
Both serum and tissue sample extraction proce-
dure involved a liquid-liquid extraction. Before use,
tissue samples were thawed, an aliquot of 200 mg
was weighed and placed in a glass mortar and pestle
tissue grinder. The tissues were homogenized with
0.5 mL of phosphate buffer (pH 7.4), and 0.5 mL of
homogenates were transferred to new glass cen-
trifuge tubes and spiked with 50 µL of the internal
standard working solution (50 mg ◊ mL
-1
). Similarly,
Figure 2. Representative chromatograms: drug-free rat serum sample (A), rat serum sample containing IS, PTX and M1 at a concentration
of 1 mg ◊ mL-1 (B), serum sample from a rat receiving PTX at intraperitoneal dose of 50 mg ◊ kg-1 (C), drug-free rat kidney sample (D),
rat kidney sample containing IS, PTX and M1 at a concentration of 1 mg ◊ mL-1 (E), kidney sample from a rat receiving PTX at intraperi-
toneal dose of 50 mg ◊ kg-1 (F).
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0.5 mL of rat serum was also spiked with 50 µL of
the internal standard working solution. Serum and
tissue samples were acidified with 0.1 mL of
hydrochloric acid (0.1 M), shaken with 3 mL of a
mixture of dichlorometane ñ chloroform (50:50, v/v)
for 20 min and then centrifuged (2000 g, 15 min).
Two mL of the organic phase was evaporated to dry-
ness under a stream of nitrogen. The dried residue
was reconstituted in 100 µL of the mobile phase and
a 50 µL volume was injected into the HPLC column.
Stability study
Stability of the analytes was determined peri-
odically by injecting replicate preparations of
processed samples. The peak areas of the analyte
and IS obtained in the initial cycle were used as the
reference to determine the stability at subsequent
points. The stability of each compound in the matrix
over 6 h (bench-top) was determined at an ambient
temperature (25 ± 3OC) at concentrations of three
QC samples (0.015, 0.5 and 4 µg ◊ mL
-1
). Freezer
stability of the compounds in rat serum and tissues
was assessed by analyzing the QC samples stored at
ñ 30 and ñ 80OC, respectively, for four weeks. The
stability of each compound was also assessed after
three freeze/thaw cycles using three levels of QC
samples. Serum and tissue samples were stored at 
ñ 30 and ñ 80OC, respectively. Between freeze/thaw
cycles, samples were thawed by allowing them to
stand at room temperature for approximately 1 h.
The samples were then returned to the freezer. 
Samples were considered to be stable if assay
values were within the acceptable limits of accuracy
and precision.
Assay validation
Specificity of the method was investigated by
analysis of six different batches of pooled blank rat
serum and tissue homogenate samples, to determine
whether endogenous constituents coeluted with the
different analytes. The retention times of endoge-
nous compounds in the matrix were compared with
that of the compounds of interest. 
Replicate injections (n = 6) of a solution con-
taining the racemic mixture of M1 at a concentration
of 1 mg ◊ mL
-1
have shown two different peaks,
each of them corresponding to an enantiomer, with
an area ratio of 0.998 ± 0.08. 
Standard calibration curves were obtained
from an unweighted, least-squares linear regression
analysis of the data. The slope and intercept of the
calibration graphs were determined through linear
regression of the drug to an internal standard peak
area ratio versus drug concentration plot (formula:
y = ax + b; where x = concentration and y = peak
area ratio). Individual peak area ratios were then
interpolated on the calibration graphs to determine
the values of the concentration found (back-calcu-
lated concentration) as compared to the concentra-
tion added.
Quality of fit was evaluated by comparing
back-calculated concentrations to the nominal ones.
The ìlack of fitî test was used to confirm the linear-
Table 1. Chromatographic separation of the compounds in rat serum (n = 3)
Compound  
Parameters ± SD IS PTX (-)-(R)-M1  
kí 1.93 ± 0.016 5.18 ± 0.012 6.9 ± 0.04
R.S.D. = 0.83% R.S.D. = 0.22% R.S.D. = 0.59%
α1 2.67 ± 0.025 R.S.D. = 0.94%
α2 1.33 ± 0.0057 R.S.D. = 0.58%  
Rs 1.94 ± 0.06 R.S.D. = 2.93%  
Figure 3. Serum concentration of PTX, (-)-(R)-M1 and (+)-(S)-M1
after intraperitoneal administration of PTX at a dose of 50 mg ◊
kg-1 in rat (semilogarithmic plot).
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Table 2. Assessment of intra- and inter-day precision, accuracy and recovery of the method for PTX, (n = 5 to 6)
Intraday reproducibility Interday reproducibility 
Nominal Mean Mean
concentration Equation back-calculated Precision Accuracy back-calculated Precision Accuracy Recovery
[µg ◊ mL-1]* of regression concentration [%] [%] concentration [%] [%] [%]
[µg ◊ g-1]** [µg ◊ mL-1]* [µg ◊ mL-1]*
[µg ◊ g-1]** [µg ◊ g-1]**
Serum y = 0.002x -
0.015 0.008 0.0135 ± 0.002 14.8 90 0.0138 ± 0.002 14.5 92 96.3 ± 4.3
4 4.12 ± 0.12 2.9 103 4.21 ± 0.18 4.3 105 91.7 ± 12.5
80 R2 = 0.977 84.7 ± 2.6 3.1 106 82.8 ± 6.8 8.2 103.5 112.3 ± 5.6
Liver y = 0.002x -
0.015 0.014 0.0138 ± 0.002 14.5 92 0.0145 ± 0.001 6.9 96.7 91.2 ± 3.6
4 3.93 ± 0.14 3.6 98.3 4.17 ± 0.12 2.9 104.3 96.3 ± 11.2
80 R2 = 0.986 87.5 ± 3.5 4 109.4 90.4 ± 4.1 4.5 113 89.5 ± 7.8 
Lung y = 0.002x -
0.015 0.005 0.0144 ± 0.002 13.9 96 0.0137 ± 0.002 14.6 91.3 89.7 ± 3.3
4 4.22 ± 0.17 4 105.5 3.88 ± 0.15 3.9 97 95.2 ± 11.6
80 R2 = 0.981 91.4 ± 4.6 5 114.3 86.7 ± 7.8 9 108.4 97.5 ± 8.5
Kidney y = 0.002x -
0.015 0.0017 0.0158 ± 0.002 12.7 105.3 0.0142 ± 0.002 14.1 94.7 85.4 ± 4.7
4 4.17 ± 0.21 5 104.3 3.57 ± 0.19 5.3 89.3 111.7 ± 12.5
80 R2 = 0.982 88.3 ± 2.8 3.2 110.4 89.2 ± 8.5 9.5 111.5 110.4 ± 7.8
Heart y = 0.002x -
0.015 0.021 0.0172 ± 0.002 11.6 114.7 0.0139 ± 0.002 14.4 92.7 86.7 ± 4.1
4 3.81 ± 0.12 3.2 95.3 4.23 ± 0.18 4.3 105.8 90.8 ± 15.8
80 R2 = 0.982 89.1 ± 7.5 8.4 111.4 91.5 ± 6.4 7 114.4 92.3 ± 8.3
Spleen y = 0.002x -
0.015 0.0024 0.0165 ± 0.002 12.1 110 0.0138 ± 0.002 14.5 92 87.8 ± 3.1
4 3.86 ± 0.13 3.4 96.5 4.27 ± 0.21 4.9 106.8 88.4 ± 16.6
80 R2 = 0.988 91.4 ± 4.5 4.9 114.3 90.4 ± 5.3 5.9 113 106.5 ± 9.4
* serum; * * tissue
Table 3. Assessment of intra- and interday precision, accuracy and recovery of the method for (-)-(R)-M1, (n = 5 to 6)
Intraday reproducibility Interday reproducibility 
Nominal Mean Mean
concentration Equation back-calculated Precision Accuracy back-calculated Precision Accuracy Recovery
[µg ◊ mL-1]* of regression concentration [%] [%] concentration [%] [%] [%]
[µg ◊ g-1]** [µg ◊ mL-1]* [µg ◊ mL-1]*
Serum y = 0.003x -
0.015 0.004 0.0138 ± 0.002 14.5 92 0.016 ± 0.002 12.5 107 92.2 ± 3.3
4 3.82 ± 0.18 4.7 95.5 4.23 ± 0.16 3.8 106 109.7 ± 15.5
80 R2 = 0.982 87.4 ± 9.3 10.6 109 89.2 ± 6.6 7.4 112 88.5 ± 14.2
Liver y = 0.003x -
0.015 0.008 0.0136 ± 0.002 14.7 90.7 0.0144 ± 0.002 13.8 96 90.2 ± 4.6
4 4.44 ± 0.23 5.2 111 3.87 ± 0.12 3.1 96.8 109.3 ± 14.2
80 R2 = 0.974 91.2 ± 7.5 8.2 114 85.7 ± 7.3 8.5 107  91.4 ± 12.7
Lung y = 0.003x -
0.015 0.005 0.014 ± 0.002 14.3 93.3 0.017 ± 0.002 11.8 113 87.5 ± 4.3
4 4.52 ± 0.19 4.2 113 3.88 ± 0.17 4.4 97 107.2 ± 11.6
80 R2 = 0.988 89.5 ± 7.9 8.8 112 90.2 ± 7.9 8.8 113 90.7 ± 10.5
Kidney y = 0.003x -
0.015 0.002 0.017 ± 0.002 11.8 113 0.0132 ± 0.002 15.1 88 83.4 ± 3.7
4 3.88 ± 0.11 2.8 97 3.87 ± 0.18 4.7 96.8 111.3 ± 14.5
80 R2 = 0.986 85.7 ± 6.8 7.9 107 89.2 ± 7.7 8.6 112 107.3 ± 12.4
Heart y = 0.003x -
0.015 0.004 0.0162 ± 0.002 12.3 108 0.0162 ± 0.003 12.3 108 88.6 ± 3.1
4 3.90 ± 0.11 2.8 97.5 4.26 ± 0.27 6.3 107 114.8 ± 17.8
80 R2 = 0.978 90.3 ± 7.2 8 113 90.8 ± 9.1 10 114 89.2 ± 10.5 
Spleen y = 0.003x -
0.015 0.006 0.0145 ± 0.002 13.8 93.3 0.0139 ± 0.002 14.4 92.7 92.1 ± 4.3
4 4.45 ± 0.13 2.9 111 4.28 ± 0.25 5.8 107 89.3 ± 18.6
80 R2 = 0.983 82.8 ± 7.4 8.9 104 88.5 ± 3.6 4.1 111 107.5 ± 11.6
* serum; ** tissue
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Figure 4. Tissue concentration of PTX, (+)-(S)-M1 and (-)-(R)-M1 after intraperitoneal administration of PTX at a dose of 50 mg ◊ kg-1 in
rat (semilogarithmic plot).
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ity of the method.
Intra-day precision and accuracy of the assay
were assessed by performing replicate (n = 5 to 6)
analyses of QC samples in the serum and tissue
against a calibration curve. The procedure was
repeated on different days on the same spiked stan-
dards to determine inter-day repeatability. 
Accuracy (percent of recovery) was evaluated
as (mean found concentration/theoretical concentra-
tion) ◊ 100. Precision was given by the percent rel-
ative standard deviation (R.S.D.).
Lower limit of detection (LLOD) was the low-
est detected concentration of the analyte in a sample
based on the signal to noise ratio 3:1. LLOD was
determined by the analysis of a sample with known
concentrations of the analyte and by establishing the
minimum level at which the analyte can be detected. 
Figure 5. Tissue to serum AUC ratios for PTX, (-)-(R)-M1 and
(+)-(S)-M1.
Table 4. Stability of PTX in rat serum, (n = 6)
Nominal concentration [µg ◊ mL-1] 
0.015 0.5 4
Sample Observed Observed Observed
condition concentration % Dev concentration % Dev concentration % Dev
[µg ◊ mL-1] [µg ◊ mL-1] [µg ◊ mL-1]
Freshly 
prepared 
0.0134 -10.7 0.542 8.4 4.27 6.8
6 h at room
temperature
0.0142 -5.3 0.462 -7.6 3.86 -3.5
4 weeks at 
-30OC
0.0164 9.3 0.544 8.8 4.13 3.3 
Freeze/thaw 
cycle 
0.0169 12.7 0.471 -5.8 3.71 -7.3
% Dev ñ percent error
Table 5. Stability of (-)-(R)-M1 in rat serum, (n = 5 to 6)
Nominal concentration [µg ◊ mL-1] 
0.015 0.5 4
Sample Observed Observed Observed
condition concentration % Dev concentration % Dev concentration % Dev
[µg ◊ mL-1] [µg ◊ mL-1] [µg ◊ mL-1]
Freshly 
prepared 
0.0139 -7.3 0.553 10.6 4.12 3
6 h at room
temperature
0.0136 -9.3 0.461 -7.8 3.81 -4.8
4 weeks at 
-30OC
0.0165 10 0.470 -6 4.109 2.7
Freeze/thaw 
cycle 
0.0172 14.7 0.561 12.2 3.912 -2.2
% Dev ñ percent error
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Lower limit of quantification (LLOQ) was defined
as the lowest drug concentration which can be quan-
titatively determined with a precision = 20%, and an
accuracy of 100 ± 20%, and it was the lowest stan-
dard on the calibration curve. 
Extraction recoveries of PTX and (-)-(R)-M1
in all studied matrices were evaluated at five to six
replicates preceded by extraction procedure of spik-
ing drug-free serum and drug-free tissue
homogenate samples with low, medium and high
QC levels of the analytes. The relative recovery was
examined by comparing the peak areas of the
extracted samples with equal amounts of solutions
of the analytes injected directly into the HPLC col-
umn. Moreover, extraction recovery in the serum
and tissues was calculated for the IS, at the concen-
tration of 5 µg ◊ mL
-1
. 
A pilot pharmacokinetic study in rat
Using the chiral HPLC-UV method, a pilot
pharmacokinetic profile and tissue distribution of
PTX and enantiomers of its chiral metabolite M1
were studied, after intraperitoneal dosing of PTX in
rats. 
Male Wistar rats, 13-15 weeks of age and
weighing between 200 and 220 g were used. They
were kept under conditions of a constant temperature
(21-25OC) and a relative humidity of approximately
40-65% with a standard light/dark cycle. The animals
were housed in stainless steel cages with suspended
wire-mesh floors (maximum of 5 rats per cage). The
animals were fasted overnight and then weighed. The
rats had free access to water throughout the experi-
mental period. PTX dissolved in 0.9% sterile isotonic
saline at a dose of 50 mg ◊ kg
-1
was administered
intraperitoneally. The rats were anaesthetized with
thiopental at a dose of 60 mg ◊ kg
-1
and blood sam-
ples were collected from the left jugular vein to
microfuge tubes at the following time intervals: 0
(predose), 5, 15, 30, 45, 60 and 120 min after dosing.
Six rats at a time were sampled, and one sample per
rat was collected. The serum and tissue samples were
stored at ñ 30OC and ñ 80OC, respectively, until used. 
RESULTS AND DISCUSSION
The previously published analytical methods
allowed the measurement of the parent drug and its
metabolites M1, M2, M4 and M5, as a racemic com-
pounds in human (12), rabbit (18), mouse (19), dog
(20) and horse (21) biological fluids, but determina-
tions of these compounds, especially the enan-
tiomers of metabolite M1 in rat biological matrices
were rather underdone.
The present essay described a simple, reliable,
sensitive and enantioselective method for direct
analysis of PTX and (-)-(R)-M1 in rat serum and
some tissues.
Representative chromatograms of serum and
kidney tissue extracts are shown in Figure 2. On
chromatograms from blank matrices, no endogenous
interfering peaks were visible at the retention times
of the analytes (Figure 2A and 2D). Under the chro-
matographic conditions described, the retention
times from serum were 6.6 ± 0.1, 15.9 ± 0.3, 19.2 ±
0.2 and 25 ± 0.2 min for IS, PTX, (-)-(R)-M1 and
(+)-(S)-M1, respectively. The retention times of the
studied compounds from tissues were the same.
Good resolution of the analytes from endoge-
nous compounds was obtained. The retention factors
(kí) were 1.93, 5.18 and 6.9 for IS, PTX and (-)-(R)-
M1, respectively. The separation factors α1 (PTX
and IS separation) and α2 [(-)-(R)-M1 and PTX sep-
aration] were 2.67 and 1.33, respectively. There was
a clear resolution between the two enantiomers with
the resolution factor (RS) = 1.94 (Table 1). 
Calibration curves for PTX and (-)-(R)-M1 in
the serum and tissues were linear over of the studied
concentration range (0.01 to 100 mg ◊ mL
-1
). The
equations of regression for PTX and for (-)-(R)-M1
in the serum and studied tissues are presented in
Tables 2 and 3. The coefficients of correlation
obtained using a linear regression analysis were
higher than 0.974. No significant deviation from
zero was found for the intercepts, and the ìlack of
fitî test showed no significant deviation from linear-
ity. For each point of the calibration standards, the
concentrations were back-calculated from the equa-
tion of the linear regression curves, and precision
and accuracy values were calculated. 
Precision data for intra- and inter-day PTX
determination in all studied matrices were from 2.9
to 14.8% and from 2.9 to 14.6%, and for (-)-(R)-M1,
they were from 2.8 to 14.7% and from 3.1 to 15.1%,
respectively. Within-batch and between-batch accu-
racy values for PTX ranged from 90 to 114.7% and
from 89.3 to 114.4%, and for (-)-(R)-M1, they were
from 90.7 to 114% and from 88 to 114%, respec-
tively (Tables 2 and 3). 
Linear regression of the back-calculated con-
centrations versus the nominal ones provided a unit
slope and an intercept equal to zero (Studentís t-
test). The distribution of the residuals (difference
between nominal and back-calculated concentra-
tions) shows random variations, the number of pos-
itive and negative values being approximately equal.
Moreover, they were normally distributed and cen-
tered around zero. 
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In all studied matrices, the lower limit of quan-
tification of the method was found to be 0.01 mg ◊
mL
-1
for both PTX and (-)-(R)-M1 and was deter-
mined with high precision and accuracy, not exceed-
ing 20 and 120%, respectively. On the basis of the
signal to noise ratio value (3:1) obtained in the
experiment, the lower limit of detection was five-
fold lower and equal to 0.002 mg ◊ mL
-1
.
High and reproducible recoveries were
obtained for all compounds investigated by compar-
ing the peak areas of the extracted samples versus
equal amounts of solutions at 0.015, 4 and 80 mg ◊
mL
-1
concentrations of the analytes. The relative
extraction recoveries for PTX and (-)-(R)-M1 from
all matrices were from 85.4 ± 4.7% to 112.3 ± 5.6%
and from 83.4 ± 3.7% to 114.8 ± 17.8%, respective-
ly. For the IS, at a concentration of 5 mg ◊ mL
-1
, the
mean extraction recovery was found to be 75.1 ±
4.36%. Extraction efficiency was independent of the
concentration over the range studied. The liquid-liq-
uid extraction procedure is simpler to develop,
requires much less expensive equipment and
remains a useful alternative when a large number of
samples have to be analyzed. 
Over a 6 h period of the short-term stability
test, the predicted concentrations for PTX and (-)-
(R)-M1 with QC samples deviated within 15% of
the nominal concentrations, and no significant
degradation could be detected in the samples. The
data also reflect the stability of the compounds dur-
ing the freezing process. PTX and (-)-(R)-M1 were
found to be stable in the serum and tissues when
stored at ñ 30 and ñ 80OC, respectively, for at least
four weeks. The results of QC samples following
three repeated freeze/thaw cycles have shown that
the analytes were stable in the frozen serum at 
ñ 30OC and in frozen tissues at ñ 80OC. The data of
stability tests for PTX and (-)-(R)-M1 from serum
are presented in Tables 4 and 5, respectively.
For verification of this method for possible
application in a pilot pharmacokinetic study of pen-
toxifylline, PTX was administered intraperitoneally
at a dose of 50 mg ◊ kg
-1
to male Wistar rats. Due to
the lack of the reference substance available, the
(+)-(S)-M1 enantiomer was quantified in serum and
tissues from a calibration curve prepared from the
M1 racemic compound. 
In the animalís treatment group, PTX, (-)-(R)-
M1 and (+)-(S)-M1 concentrations declined over
time in a log-linear fashion (Figure 3). 
Tissue distribution of the parent drug and the
enantiomers of its active metabolite M1 was investi-
gated in liver, lung, kidney, heart and spleen. Figure
4 illustrates the tissue concentration of PTX, 
(+)-(S)-M1 and (-)-(R)-M1 after pentoxifylline
intraperitoneal administration. Significant (p < 0.05)
differences between serum and tissue levels of PTX,
(-)-(R)-M1 and (+)-(S)-M1 were observed.
Interestingly, in all studied matrices, the areas under
the concentration ñ time curve calculated for 
(+)-(S)-M1 were higher than that observed for 
(-)-(R)-M1. 
Tissue to serum AUC0→inf ratios for all studied
compounds after PTX intraperitoneal dosing are
presented in Figure 5. For PTX, these ratios were
very low and ranged from 0.12 for the liver to 0.71
for the heart tissue. On the contrary, for (-)-(R)-
M1, the tissue to serum AUC0→inf ratios were high,
with the highest value (32.5) observed in the
spleen. In the case of (+)-(S)-M1, the highest tissue
to serum AUC0→inf values (4.3) were observed in
the kidney. Based on the above results, it can be
concluded that the developed and validated analyt-
ical method allows for the analysis of all com-
pounds of interest in rat biological matrices and is
useful for a routine pharmacokinetic study of PTX
and its pharmacologically active metabolite, 
(-)-(R)-M1, in rat. 
CONCLUSIONS
We described a simple, sensitive and selective
chiral, normal-phase, high-performance liquid chro-
matography method with UV detection for the
analysis of PTX and its pharmacologically active
metabolite, (-)-(R)-M1, in rat biological matrices.
This method is accurate and suitable for daily direct
enantioselective analysis of (-)-(R)-M1 in the pres-
ence of PTX. The good sensitivity, separation effi-
ciency and reproducibility of the method were
achieved for all biological matrices and allow one to
perform pharmacokinetic studies of pentoxifylline
in rat matrices. The lower limit of quantification,
QC accuracy and precision were well within the
range generally accepted for bioanalytical methods.
This method was successfully applied to pilot phar-
macokinetic studies of PTX and its active metabo-
lite, (-)-(R)-M1, in rats following PTX intraperi-
toneal dosing. 
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